KVISTGAARD, Denmark, June 1, 2011 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (Copenhagen:BAVA) today announced that investigators from the National Cancer Institute are presenting at the 2011 ASCO Annual Meeting in Chicago data from a study with PROSTVAC® entitled “Intraprostatic PSA-TRICOM vaccine administration in patients with locally recurrent prostate cancer”.
